Wednesday, July 8, 2026

Patent intelligence · US

US 10881646

Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers

granted A61KA61K31/4439A61K31/506A61K31/519
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 14
Applicant portfolio 706
Patent details — US 10881646
Jurisdiction
US
Status
granted
Grant date
Jan 5, 2021
Expiration
Dec 31, 2040
Claims
12
CPC classes
A61K, A61K31/4439, A61K31/506, A61K31/519
View on Google Patents ↗

Quick answer

US 10881646 (Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers) is held by Biomed Valley Discoveries, Inc.. Status: granted. Granted Jan 5, 2021. Expires Dec 31, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
12
CPC classes
A61K, A61K31/4439, A61K31/506, A61K31/519, A61K45/06, A61P

More from Biomed Valley Discoveries, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12427173

    Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies

    Biomed Valley Discoveries, Inc. · Expires Sep 25, 2045

    granted
  2. US 12428415

    Matriptase 2 inhibitors and uses thereof

    Disc Medicine, Inc. · Expires Sep 25, 2045

    granted
  3. US 12421236

    Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

    Medshine Discovery Inc. · Expires Sep 18, 2045

    granted
  4. US 12420085

    Synergistic therapies for inter vertebral disc degeneration

    Discure Technologies Ltd · Expires Sep 18, 2045

    granted
  5. US 12421231

    Azaindole derivatives and their use as ERK kinase inhibitors

    AGV Discovery · Expires Sep 18, 2045

    granted
  6. US 12403069

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Expires Aug 28, 2045

    granted
  7. US 12398179

    Nanomolar peptides and derivatives to differentially modulate ephrin receptors

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Expires Aug 21, 2045

    granted
  8. US 12396924

    Adapter for use in a planetary mixer

    MEDISCA PHARMACEUTIQUE INC. · Expires Aug 21, 2045

    granted

Frequently asked questions

What is US patent 10881646?

US 10881646 (Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers) is held by Biomed Valley Discoveries, Inc.. Status: granted. Granted Jan 5, 2021. Expires Dec 31, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10881646?

Biomed Valley Discoveries, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 706 pharmaceutical patents for this assignee.

When does US 10881646 expire?

Our index shows an expiration date of Dec 31, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.